UTHR - United Therapeutics Corporation
United Therapeutics Corporation
1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 985
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO | 5,32M | 56,15M | 1955 |
| Mr. Michael I. Benkowitz | Pres & COO | 2,83M | 7,83M | 1972 |
| Mr. James C. Edgemond | CFO & Treasurer | 2,01M | 1,49M | 1968 |
| Mr. Paul A. Mahon J.D. | Exec. VP, Gen. Counsel & Corp. Sec. | 2,31M | 13,2M | 1964 |
| Mr. Dewey Steadman C.F.A. | Head of Investor Relations | N/D | N/D | N/D |
| Ms. Holly Hobson | Associate VP of HR | N/D | N/D | N/D |
| Kevin T. Gray | Sr. VP of Strategic Operations & Logistics | N/D | N/D | N/D |
| Mr. Patrick Poisson | Exec. VP of Technical Operations | N/D | N/D | 1968 |
| Dr. Leigh Peterson | Sr. VP of Product Devel. | N/D | N/D | N/D |
| Mr. Gil Golden | Sr. VP & Chief Medical Officer | N/D | N/D | N/D |
Descrizione
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Governance aziendale
L'ISS Governance QualityScore di United Therapeutics Corporation al 1 giugno 2023 è 4. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 3; retribuzione: 5.
